| Neuropharmacology of quinolinic and kynurenic acids. TW Stone Pharmacological reviews 45 (3), 309-379, 1993 | 1130 | 1993 |
| An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid MN Perkins, TW Stone Brain research 247 (1), 184-187, 1982 | 984 | 1982 |
| Endogenous kynurenines as targets for drug discovery and development TW Stone, LG Darlington Nature reviews Drug discovery 1 (8), 609-620, 2002 | 932 | 2002 |
| Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS TW Stone, MN Perkins European journal of pharmacology 72 (4), 411-412, 1981 | 872 | 1981 |
| Physiological roles for adenosine and adenosine 5′-triphosphate in the nervous system TW Stone Neuroscience 6 (4), 523-555, 1981 | 579 | 1981 |
| The kynurenine pathway and the brain: Challenges, controversies and promises R Schwarcz, TW Stone Neuropharmacology 112, 237-247, 2017 | 406 | 2017 |
| Activation of brown adipose tissue thermogenesis by the ventromedial hypothalamus MN Perkins, NJ Rothwell, MJ Stock, TW Stone Nature 289 (5796), 401-402, 1981 | 385 | 1981 |
| Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders LG Darlington, TW Stone British Journal of Nutrition 85 (3), 251-269, 2001 | 379 | 2001 |
| An expanding range of targets for kynurenine metabolites of tryptophan TW Stone, N Stoy, LG Darlington Trends in pharmacological sciences 34 (2), 136-143, 2013 | 374 | 2013 |
| Kynurenines in the CNS: from endogenous obscurity to therapeutic importance TW Stone Progress in neurobiology 64 (2), 185-218, 2001 | 356 | 2001 |
| Quinolinic acid and other kynurenines in the central nervous system TW Stone, JH Connick Neuroscience 15 (3), 597-617, 1985 | 356 | 1985 |
| Tryptophan metabolism and oxidative stress in patients with Huntington's disease N Stoy, GM Mackay, CM Forrest, J Christofides, M Egerton, TW Stone, ... Journal of neurochemistry 93 (3), 611-623, 2005 | 353 | 2005 |
| Obesity and cancer: existing and new hypotheses for a causal connection TW Stone, M McPherson, LG Darlington EBioMedicine 30, 14-28, 2018 | 287 | 2018 |
| The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders TW Stone, LG Darlington British journal of pharmacology 169 (6), 1211-1227, 2013 | 276 | 2013 |
| NMDA receptors and ligands in the vertebrate CNS TW Stone, NR Burton Progress in neurobiology 30 (4), 333-368, 1988 | 274 | 1988 |
| Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl WMH Behan, M McDonald, LG Darlington, TW Stone British journal of pharmacology 128 (8), 1754-1760, 1999 | 270 | 1999 |
| Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system. MN Perkins, TW Stone The Journal of pharmacology and experimental therapeutics 226 (2), 551-557, 1983 | 268 | 1983 |
| Adenosine receptors and neurological disease: neuroprotection and neurodegeneration TW Stone, S Ceruti, MP Abbracchio Adenosine receptors in health and disease, 535-587, 2009 | 266 | 2009 |
| Cyclic AMP and cyclic GMP may mediate opposite neuronal responses in the rat cerebral cortex TW Stone, DA Taylor, FE Bloom Science 187 (4179), 845-847, 1975 | 253 | 1975 |
| The gut-brain axis, BDNF, NMDA and CNS disorders R Maqsood, TW Stone Neurochemical research 41, 2819-2835, 2016 | 250 | 2016 |
